Damora Therapeutics (DMRA) Research & Development (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Research & Development came in at $23.8 million in Q1 2026, up 3406.93% YoY from $678000.0 in Q1 2025, and up 1.97% on a QoQ basis from $23.3 million in Q4 2025.
Damora Therapeutics (DMRA) Research & Development (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Research & Development data on file, last reported at $23.8 million in Q1 2026.
- Quarterly Research & Development rose 3406.93% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.0 million (up 983.37% YoY) and the FY2025 annual result came in at $26.9 million, up 320.08% from the prior year.
- Research & Development rose to $23.8 million in Q1 2026, from $23.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $23.8 million in Q1 2026 to a low of $678000.0 in Q1 2025.
- A 5-year average of $7.6 million and a median of $2.8 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 77.33% — and 2026, when it surged 3406.93%.
- Tracing DMRA's Research & Development over 5 years: stood at $10.8 million in 2022, then slumped by 74.3% to $2.8 million in 2023, then slumped by 63.58% to $1.0 million in 2024, then surged by 2213.29% to $23.3 million in 2025, then advanced by 1.97% to $23.8 million in 2026.
- The last three Research & Development figures came in at $23.8 million (Q1 2026), $23.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 25.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.54 Mn |
| Mar 31, 2026 | 23.78 Mn |
| Dec 31, 2025 | 23.32 Mn |
| Sep 30, 2025 | 1.42 Mn |
| Jun 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | 678,000.00 |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 2.46 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | 2.55 Mn |
| Jun 30, 2023 | 8.09 Mn |
| Mar 31, 2023 | 10.36 Mn |
| Dec 31, 2022 | 10.77 Mn |
| Sep 30, 2022 | 10.49 Mn |
| Jun 30, 2022 | 13.71 Mn |
| Mar 31, 2022 | 13.24 Mn |
| Dec 31, 2021 | 10.12 Mn |
| Sep 30, 2021 | 9.75 Mn |